Algeta, Aspiring For Solo Success, Draws Bayer Bid After Xofigo Launch
The Norwegian biotech is keen to show it is not a one-trick pony, but its future might lie in the embrace of its big pharma partner Bayer.
You may also be interested in...
Norwegian start-up CardiNor is developing a new cardiovascular biomarker, and is hopeful of attracting cash in a country where investor traditions are undergoing some changes. The financial pressures caused by falling oil prices have brought renewed attention to life science companies.
France’s Advanced Accelerator Applications is making plans to extend its business to the US after its lead radiotherapeutic, a lutetium labelled somatostatin analog, met its primary endpoint in a Phase III study.
The committed capital is nearly half what the 40-year-old firm raised from its previous vehicle and its sidecar in 2007–2008, but it's a huge sum compared with what most life science VCs can drum up these days.